TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04051944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Description: Subjects will receive rozanolixizumab in a specified sequence during the treatment period.
Study: NCT00675129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical behavioral therapy for adolescents (DBT-A)
Description: Patients randomised to DBT-A will receive 16 weeks treatment, with one weekly session (60 minutes)of individual therapy, one weekly session of multifamily skills training (120 minutes), and telephone coaching outside therapy sessions.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus \& Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Patients randomised to EUC will received standard care (16 weeks) at five participating child and adolescent outpatient clinics from therapists not trained in or practising DBT. According to pilot study data EUC will most likely consist of psychodynamic therapy, various forms of family therapy and supportive therapy.
Study: NCT01982669

Intervention type: OTHER
Intervention: No Intervention
Study: NCT02393989

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: posterior restoration
Description: restorations for caries effected teeth
Study: NCT02466906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhGM-CSF
Description: rhGM-CSF was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. During adjuvant therapy of XELOX, rhGM-CSF was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15) or stopped when ANC\>20.0X109/L.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. . During adjuvant therapy of XELOX, placebo was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15).
Study: NCT01873599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect Journaling
Study: NCT01066611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAL-263
Description: CAL-263 10 mg or placebo once daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: CAL-263 10 mg or placebo once daily for 7 days
Study: NCT00045019

Intervention type: OTHER
Intervention: quality-of-life assessment
Description: QLQ-C30 SAT32
Study: NCT03563651

Intervention type: PROCEDURE
Intervention: Biopsy
Description: Undergo biopsy
Study: NCT04549675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sun Safe Partners Online
Description: Sun Safe Partners Online has 4 individual-focused modules and 4 couple-focused modules focusing on skin cancer prevention education and sun protection.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Generic Online Sun Safety Information intervention
Description: 4 links to sent to participants from (1) The Skin Cancer Foundation's Skin Cancer Prevention guidelines, (2) the Centers for Disease Control and Prevention's information on risk factors for skin cancer, (3) the American Academy of Dermatology's information on how to select an appropriate sunscreen, and (4) The Skin Cancer Foundation's information on sun protective clothing. Participants were emailed a link to one of the resources each week for 4 weeks.
Study: NCT03869489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal left dorsolateral prefrontal cortex tDCS stimulation
Description: Anodal tDCS will be applied to the left dorsolateral prefrontal cortex of participants

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal right dorsolateral prefrontal cortex tDCS stimulation
Description: Anodal tDCS will be applied to the right dorsolateral prefrontal cortex of participants

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS stimulation
Description: Sham tDCS stimulation will be applied
Study: NCT03112499

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCNL
Description: Under general anesthesia and patient in prone position, with the use of a flexible cystoscope an open-ended ureteral catheter 5F / 70cm is positioned to the proximal ureter. Retrograde pyelography is performed and the most appropriate calyx is accessed with the use of ultrasound, under fluoroscopic guidance. A 0.035 guide wire is inserted into the ureter and then replaced with an extra stiff wire. Using either balloon (20 atm) or Amplatz serial dilators a 30F access channel is created. Lithotripsy is performed using ultrasound lithotripter and stone fragments are removed by grasping forceps. At the end of the operation a 18F Council type catheter is placed into the kidney for drainage of urine and an indwelling JJ catheter is inserted in the ipsilateral ureter. Council and JJ catheter are removed,in the absence of complications, the second and tenth postoperative day, respectively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mini-PCNL
Description: Under general anesthesia and patient in prone position, with the use of a flexible cystoscope an open-ended ureteral catheter 5F / 70cm is positioned to the proximal ureter. Retrograde pyelography is performed and the most appropriate calyx is accessed with the use of ultrasound, under fluoroscopic guidance. A 0.035 guide wire is inserted into the ureter and then replaced with an extra stiff wire. Using Amplatz serial dilators a 16F access channel is created. Lithotripsy is performed using using 270mm Ho: YAG laser fiber and stone fragments are removed by grasping forceps. At the end of the operation a 10F nephrostomy tube is placed into the kidney for drainage of urine and an indwelling JJ catheter is inserted in the ipsilateral ureter. Nephrostomy tube and JJ catheter are removed, in the absence of complications, the second and tenth postoperative day, respectively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RIRS
Description: Under general anesthesia and patient in lithotomy position, a 0.035 hydrophilic safety wire is inserted in the ureter under fluoroscopic guidance. Subsequently 8-10 F dilators are used for dilation of the ureter.Insertion of a second working wire follows above which a 14F ureteral sheath is placed. Lithotripsy with a flexible ureteroscope using 270mm Ho: YAG laser fiber follows.Remaining stone fragments are removed by a 2,2F nitinol basket. At the end of the operation a JJ indwelling ureteral catheter is placed over the safety wire. Discharge is performed in the absence of complications, the first postoperative day while JJ catheter is removed on the 10th postoperative day.
Study: NCT03523715

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prunes
Description: 12 oz of prunes daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docusate Sodium
Description: Oral docusate sodium twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docusate Sodium
Description: Oral docusate sodium twice daily
Study: NCT04684706

Intervention type: DEVICE
Group type: OTHER
Intervention: intermittent Theta Burst Stimulation
Description: The present study will utilize TMS dosage of iTBS of 18 000 pulses a day for 5 consecutive days.
Study: NCT05335785

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity lazer therapy
Description: Patients in the laser group will be given hiltherapy (high-intensity laser) with the HIRO 3 device every other day. One session of laser therapy application consists of 3 phases: the beginning, the middle and the ending phase. The initial phases are fast scanning and the ending phase is slow scanning. A total of 2000 J will be applied to the rotatorcuff muscles, the upper part of the trapezius muscle, the deltoid muscle and the pectoralis major muscle, 1000 J in the rapid scan phase and 1000 J in the finishing phase. In the middle phase, 50 J will be applied for the trigger point (hard intramuscular points that cause referred pain) in each muscle and a maximum of 500 J in total. The total dose prescribed for patients in one session will be 2500 J. Each phase will be 15 minutes on average and the session will last for 45 minutes in total. The laser probe will be applied with 90 degrees. During the application, the practitioner and the patient will have protective glasses.
Study: NCT03563651

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood, urine, and stool

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03994211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pamiparib 60 mg
Description: Single dose of 60 mg pamiparib orally on Days 1 and 10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pamiparib 20 mg
Description: Single dose of 20 mg pamiparib orally on days 1 and 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: 200 mg itraconazole once a day al Day 3 to day 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampin
Description: 600 mg rifampin once a day from days 3 to 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pamiparib
Description: 60 mg pamiparib orally twice a day in 28-day cycles
Study: NCT04662775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HERizon Project
Description: 1. Participants were asked to complete 3x30-minute physical activity sessions each week \& record their sessions using a logbook. They were given the choice of different types of home-based virtual exercise. 2. Behaviour change support calls - participants were allocated an Activity Mentor (trainee sport and exercise psychologists, was supervised by a HCPC-registered Psychologist). Participants had seven weekly videocalls. Each call was based on a pre-planned session outline and was goal orientated, participant centred and focused on physical activity. 3. No reply SMS - Participants received 3 standardised text messages each week, aimed at providing physical activity -related facts, encouragement and study information.
Study: NCT01179828

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone 15mg
Description: 15mg single administration p.o.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobazam
Description: 20mg single administration p.o.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipramine
Description: 75mg single administration p.o.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tolterodine
Description: 1 mg single administration p.o.
Study: NCT05727007

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI in colon cancer
Description: The MRI protocol will include the following imaging series: T1 and T2 in axial and coronal plane before the administration of intravenous contrast, diffuse weight imaging in axial plane and T1 after the administration of intravenous contrast

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT in colon cancer
Description: The CT scan protocol will include the following: per os and intravenous administration of contrast, axial slices of 0.3mm thickness and reconstruction per 1mm, multi-planar reformation and three-dimensional volume rendering
Study: NCT02003794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% NaCl solution
Description: 0.9% NaCl solution intravenous infusion: 100 ml/hr for three days.
Study: NCT03066960

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency neurotomy
Description: RF neurotomy represents a nerve destructive, coagulating technique affecting the conduction through all nerve fibers.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Sham treatment represents no coagulation of the nerve and will not affect the nerve conduction.
Study: NCT04550520

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Glucagon with the empirical formula of C153H225N43O49S, and a molecular weight of 3483 g/mol, is a single-chain polypeptide containing 29 amino acid residues. Glucagon is provided in a single dose vial as powder. One container contains 1 mg of glucagon which results in a concentration of 1 mg/ml after dissolution in a volume of 1 ml (Glucagen NovoNordisk (Hypokit)). The currently used standard dose regimen is 1 mg of glucagon in adults. The solution for subcutaneous injection will be prepared by the study personnel according to the attached package leaflet.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Glucagon with the empirical formula of C153H225N43O49S, and a molecular weight of 3483 g/mol, is a single-chain polypeptide containing 29 amino acid residues. Glucagon is provided in a single dose vial as powder. One container contains 1 mg of glucagon which results in a concentration of 1 mg/ml after dissolution in a volume of 1 ml (Glucagen NovoNordisk (Hypokit)). The currently used standard dose regimen is 1 mg of glucagon in adults. The solution for subcutaneous injection will be prepared by the study personnel according to the attached package leaflet.
Study: NCT03203525

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study: NCT03563651

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03654820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PVP-I solution combined with NaF varnish
Description: 4-monthly application of 10% povidone-iodine solution and 5% sodium fluoride varnish

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SDF solution
Description: Annual application of 38% SDF solution
Study: NCT01852500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Osteopathic Manipulative Treatment
Description: Patients from this group received sham osteopathic treatments twice a week for the entire length of stay in the unit.
Study: NCT04550520

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Placebo
Description: As placebo 1 ml sodium chloride (NaCl) 0.9% to inject subcutaneous is used. It has the same optical appearance as glucagon.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Placebo
Description: As placebo 1 ml sodium chloride (NaCl) 0.9% to inject subcutaneous is used. It has the same optical appearance as glucagon.
Study: NCT03316118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: Group 1 will receive genicular nerve block using bupivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Group 2 will receive genicular nerve block using normal saline
Study: NCT02613494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyoscine
Description: 300 micrograms twice daily, increasing to 300 micrograms three times daily
Study: NCT03203525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given via pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given via pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given via pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields Therapy
Description: Use NovoTTF-100L(P) system

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields Therapy
Description: Use NovoTTF-100L(P) system
Study: NCT03295994

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative
Description: Arthroscopic rotator cuff surgery followed by physical therapy.
Study: NCT02613494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: 1 milligram twice daily, increasing to 1 milligram three times daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily, increasing to placebo three times daily
Study: NCT03295994

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Operative
Description: Physical therapy (without surgery).
Study: NCT00908323

Intervention type: BIOLOGICAL
Intervention: JS7 DNA vaccine

Intervention type: BIOLOGICAL
Intervention: JS7 DNA vaccine
Study: NCT01745965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Study: NCT05335785

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity lazer therapy
Description: Patients in the laser group will be given hiltherapy (high-intensity laser) with the HIRO 3 device every other day. One session of laser therapy application consists of 3 phases: the beginning, the middle and the ending phase. The initial phases are fast scanning and the ending phase is slow scanning. A total of 2000 J will be applied to the rotatorcuff muscles, the upper part of the trapezius muscle, the deltoid muscle and the pectoralis major muscle, 1000 J in the rapid scan phase and 1000 J in the finishing phase. In the middle phase, 50 J will be applied for the trigger point (hard intramuscular points that cause referred pain) in each muscle and a maximum of 500 J in total. The total dose prescribed for patients in one session will be 2500 J. Each phase will be 15 minutes on average and the session will last for 45 minutes in total. The laser probe will be applied with 90 degrees. During the application, the practitioner and the patient will have protective glasses.

Intervention type: OTHER
Group type: OTHER
Intervention: Exercises
Description: Exercise program including Codman, Range of motion and streightening exercises three times in a week.
Study: NCT03397199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib + S-1
Description: Apatinib 250mg/d,q.d.,p.o. A course of treatment need 21days. S-1 40-60mg（40mg bid BSA \<1.4, 60mg bid BSA\>1.4），bid,from day1-day 14.
Study: NCT00908323

Intervention type: BIOLOGICAL
Intervention: MVA/HIV62 vaccine

Intervention type: BIOLOGICAL
Intervention: MVA/HIV62 vaccine
Study: NCT02450435

Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.
Study: NCT00261378

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterialchemoembolisation (TACE)
Study: NCT02450435

Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
Study: NCT01355679

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guided Therapy
Description: A total of 14 eligible neuroblastoma patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
Study: NCT02965794

Intervention type: OTHER
Intervention: Care pathways for colorectal cancer
Description: development of a care pathway for this patient group
Study: NCT02728648

Intervention type: DRUG
Group type: OTHER
Intervention: Oxycodone
Description: Pain Management
Study: NCT02250079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: polyethylene plastic bag
Description: Inborn neonates with both a gestational age \>29 weeks were randomized 1:1 to either a standard thermoregulation protocol or placement of a Poliethylene body bag since birth to 10 minutes after birth.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Infants randomized to the control group received standard hospital care newborn. This included immediate drying, skin-to-skin contact, early and exclusive breast feeding, postponed bathing, bundling, and radiant warmer. While waiting for criteria cord clamping, the environment humidity and temperature and segment and rectal temperature of the newborn were measure. It was repeated at 1-5- 10-60 and 120 minutes. After clamping, the newborn were positioned in a radiant warmer, and completed the drying process. Umbilical prophylaxis, vitamin K1 application, initial physical examination and ocular prophylaxis are performed. The infants were swaddled in blankets provided by the mother, the head was covered with a hat, and the infants were placed either in an open crib or under a radiant warmer as necessary and available. The same process was done in surgery room in case of cesarean.
Study: NCT03773536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine given with single low dose primaquine
Description: Three day treatment with ASAQ with SLD primaquine given with the first dose of ASAQ.
Study: NCT00884962

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polymeric Lung Volume Reduction System (PLVR)
Description: 20ml (each) of polymer will be injected into 2, 3 or 4 subsegments during the first treatment. Eligible patients may have 20ml (each) of polymer will be injected into 2 or 3 subsegments during the second treatment.
Study: NCT01584791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel napadisilate + aspirin
Description: clopidogrel napadisilate 75mg + aspirin 100mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel bisulfate + aspirin
Description: clopidogrel bisulfate 75mg + aspirin 100mg